A phase II study of active specific immunotherapy and5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma

Active specific immunotherapy, using vaccines with autologous tumour cells and BCG, significantly reduces the rate of tumour recurrence in stage II colon cancer patients, while no clinical benefit has yet been observed in stage III patients. Adjuvant treatment with 5-Fluorouracil/Leucovorin is now c...

Descripción completa

Detalles Bibliográficos
Autores principales: Baars, A, Claessen, A M E, Wagstaff, J, Giaccone, G, Scheper, R J, Meijer, S, Schakel, M J A G, Gall, H E, Meijer, C J L M, Vermorken, J B, Pinedo, H M, van den Eertwegh, A J M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375342/
https://www.ncbi.nlm.nih.gov/pubmed/11953877
http://dx.doi.org/10.1038/sj.bjc.6600254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375342/
https://www.ncbi.nlm.nih.gov/pubmed/11953877
http://dx.doi.org/10.1038/sj.bjc.6600254

Ejemplares similares